PMS29 Cost Effectiveness of Adalimumab Versus Golimumab and Placebo in Ankylosing Spondylitis in Italy
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1384
https://www.valueinhealthjournal.com/article/S1098-3015(12)03097-5/fulltext
Title :
PMS29 Cost Effectiveness of Adalimumab Versus Golimumab and Placebo in Ankylosing Spondylitis in Italy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03097-5&doi=10.1016/j.jval.2012.08.1384
First page :
A444
Section Title :
Muscular-Skeletal Disorders
Open access? :
No
Section Order :
881